Material and methods
We searched for the prospective randomized clinical trials that evaluated the efficacy and safety of different brands of rituximab for the treatment of the Bcell non-Hodgkin's lymphoma. Cost-minimization analysis of Acellbia® and MabThera® treatment was conducted from the perspective of the Russian healthcare system.
One randomised controlled trial showed similar efficacy and safety of Acellbia® and MabThera® in the treatment for the CD-positive follicular non-Hodgkin's lymphoma. Substitution with Acellbia® for MabThera® was associated with cost-saving of RUB 34,913-46,824 for a single administration and RUB 139,654-187,294 for the course of therapy.
Substitution of MabThera® with Acellbia® in the monotherapy for the CD-positive B-cell follicular nonHodgkin's lymphoma is justified clinically and economically.
Rituximab, non-Hodgkin's lymphoma, import substitution.